Patent issued for SangStat's proprietary generic cyclosporine formulation, Sang-35, SangStat CFO James Hinrichs says. The patent covers both liquid and capsule dosage forms. SangStat is awaiting FDA approval of its generic version of Novartis' Neoral and has arranged manufacturing partnerships with Gensia Sicor for the bulk substance and Lilly for finished product. The branded generic will be marketed as part of a "CycloSystem," accompanied by SangStat's CycloTech dosing device, which increases compliance by sounding an alarm at dosing time, ejecting the controlled liquid dose for consumption, and storing dosing information in a "smart chip" for up to one year
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth